How Quickly Can the Effects of Excessive Caloric Intake on Insulin Resistance be Reversed?
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19140
- Temple University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria: Healthy non-obese men and women -
Exclusion Criteria: Subjects with diabetes or a history of obesity surgery or with more than modest health problems
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: high caloric intake
Volunteers will receive 3 meals and 3 snacks over a 24 hour period which will contain ~ 6,000 calories.
Main meals will consist of ~ 1,500 calories and snacks will contain ~ 500 calories.
|
Volunteers will be started on a diet program for 4 ½ days, consisting of 3 meals and 3 snacks over a 24 hour period and containing ~ 6000 Kcal/24 h.
|
|
Other: reduced caloric intake
On days 5 and 6 subjects will receive 3 meals only and each meal will contain ~ 333 calories for a total of 1,000/ 24 hours.
|
On days 5 and 6, volunteers will received 3 meals (~333 calories each) totaling ~ 1,000 calories/24 hours.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in insulin resistance
Time Frame: baseline, day 4 and day 7
|
Insulin resistance will be determined by measuring changes in insulin-stimulated total body glucose uptake during euglycemic hyperinsulinemic clamping
|
baseline, day 4 and day 7
|
|
Changes in oxidative stress
Time Frame: baseline, day1, day 2, day 3, day 4, day 5, day 6, day 7
|
24 hour urine collections analyzed for isoprostane content
|
baseline, day1, day 2, day 3, day 4, day 5, day 6, day 7
|
|
Changes in energy expenditure
Time Frame: baseline, day 1, day 2, day 3, day 4, day 5, day 6, day 7
|
Changes in energy expenditure will be assessed with a metabolic cart (indirect calorimetry)
|
baseline, day 1, day 2, day 3, day 4, day 5, day 6, day 7
|
|
Changes in weight
Time Frame: baseline, day 1, day 2, day 3, day 4, day 5, day 6, day 7
|
Subjects will be weighed daily
|
baseline, day 1, day 2, day 3, day 4, day 5, day 6, day 7
|
|
Changes in body composition
Time Frame: baseline, day 1, day 2, day 3, day 4, day 5, day 6, day 7
|
Body composition will be determined by bioelectric impedance analysis
|
baseline, day 1, day 2, day 3, day 4, day 5, day 6, day 7
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in blood glucose levels
Time Frame: baseline, day 1, day 2, day 3, day 4, day 5, day 6, day 7
|
Daily blood samples will be analyzed to determine glucose levels of glucose.
|
baseline, day 1, day 2, day 3, day 4, day 5, day 6, day 7
|
|
Changes in blood levels of insulin
Time Frame: Baseline, day1 day2, day 3, day 4, day 5, day 6, day 7
|
Daily blood samples will be analyzed to determine insulin levels
|
Baseline, day1 day2, day 3, day 4, day 5, day 6, day 7
|
|
Changes in blood levels of free fatty acids
Time Frame: Baseline, day1 , day 2, day 3, day 4, day 5, day 6, day 7
|
Daily blood samples will be analyzed to determine free fatty acid levels
|
Baseline, day1 , day 2, day 3, day 4, day 5, day 6, day 7
|
|
Changes in blood ketone levels
Time Frame: baseline, day 1, day 2, day 3, day 4, day 5, day 6, day 7
|
Daily blood samples will be analyzed to determine ketone levels
|
baseline, day 1, day 2, day 3, day 4, day 5, day 6, day 7
|
|
Changes in glucagon levels
Time Frame: baseline, day 1, day 2, day 3, day 4, day 5, day 6, day 7
|
Daily blood samples will be analyzed to determine glucagon levels
|
baseline, day 1, day 2, day 3, day 4, day 5, day 6, day 7
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Ajaykumar Rao, MD, Temple University
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 22331
- R01DK090588 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.